Efficacy and safety of pantoprazole sodium and omeprazole treatments in patients with duodenal ulcer: a Meta-analysis
Zhang Jiaxing, Wang Zhongyuan, Xie Juan, Chen Qi, Gao Ling, Luo Lei, Li Lianhua, Xiong Shijuan, Sheng Changcheng
Published 2015-02-28
Cite as ADRJ, 2015, 17(1): 3-10. DOI: 10.3760/cma.j.issn.1008-5734.2015.01.002
Abstract
ObjectiveTo systematically evaluate the effectiveness and safety of pantoprazole sodium(PAN) and omeprazole(OME) treatments in patients with duodenal ulcer.
Methods"Pantoprazole sodium", "omeprazole", "ulcer", and "randomized controlled trial" were selected as key words and Pub Med, Embase, the Cochrane Library, VIP, CNKI, and Wanfang databases from the inception to September 2014 were searched. Randomized controlled trials(RCT) on comparison of PAN and OME treatments in patients with duodenal ulcer were selected. According to the intervention measures, the subjects were divided into the PAN group and the OME group. The medication comprised oral and intravenous administration. The Meta-analysis was performed using Rev Man 5.2 software.The outcomes included the ulcer healing rate, the pain relief rate and time, the incidence of adverse drug reactions, and the recurrence rate at six months.
ResultsA total of 17 RCTs involving 1 847 patients were entered, including 1 008 in the PAN group and 839 in the OME group. The patients in 12 RCTs received drugs by mouth and the patients in other 5 RCTs received intravenously and the Meta-analysis was performed respectively. The ulcer healing rates in patients with 2 or 4 weeks of oral PAN treatment, the pain relief rates in patients with 1, 2 or 4 weeks of oral PAN treatment were compared with those in patients with oral OME treatment at the same period and the differences were not significant. The pain relief rates in patients with 3 days of oral PAN treatment were higher than those in patients with 3 days of oral OME treatment [relative risk(RR)=1.27, 95% confidence interval(CI): 1.03-1.57, P=0.03]. The differences of the pain relief time, the incidence of adverse drug reactions, and the recurrence rates of six months between the patients with oral PAN treatment and the patients with OME treatment were not significant. The differences of the ulcer healing rates, the pain relief rates, the incidence of adverse drug reactions, and the recurrence rates of six months between the patients with intravenous PAN treatment and the patients with intravenous OME treatment were not significant.
ConclusionBoth PAN and OME are safe and effective drugs for duodenal ulcer treatment.
Key words:
Pantoprazole; Omeprazole; Duodenal ulcer; Meta-analysis
Contributor Information
Zhang Jiaxing
Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang 550002, China
Wang Zhongyuan
Xie Juan
Chen Qi
Gao Ling
Luo Lei
Li Lianhua
Xiong Shijuan
Sheng Changcheng